Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cann Global’s (CGB) joint venture (JV) partner has been handed a key export permit, which will allow its cannabis hard pills to be shipped to Australia
  • Canntab Therapeutics has been given the green light by Health Canada, meaning Cann Global can begin importing the products
  • The patented pills from Canntab are unique as they allow for precise dosing
  • CGB plans to order six different products from the pill range
  • Among the pills Cann Global has ordered are two THC products, two CBD products and two THC/CBD blends
  • The products will begin arriving in Australia next month and will be available through the Special Access Scheme B and Authorised Prescriber schemes
  • Shares in Cann Global have opened Tuesday trading steady at 0.8 cents per share

Cann Global’s (CGB) joint venture (JV) partner has been handed a key export permit, which will allow its cannabis hard pills to be shipped to Australia.

Canntab Therapeutics has been given the green light by Health Canada, while Cann Global has already secured the necessary import permits for the pills.

Following the export permit being issued, Cann advises that its order of the hard pill products will begin arriving in Australia next month.

Canntab’s products are unique because of the patented hard pill form which they come in, which allows for more precise dosing.

CGB has ordered six different products from its JV partner, including two THC products, two CBD products and two THC/CBD blends.

The CBD and THC pills will be available in Australia through both the Special Access Scheme B and Authorised prescriber schemes.

Cann is also planning to make the pills available to the Cannabinoid Medicine Observational Study (CMOS) which is testing the efficacy of cannabis on neurological and mental health conditions.

Shares in Cann Global have opened Tuesday trading steady at 0.8 cents per share at 10:06 am AEDT.

CGB by the numbers
More From The Market Herald
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering
Palla Pharma (ASX:PAL) -

" Palla Pharma (ASX:PAL) enters sale and leaseback of Coolaroo site

Palla Pharma (PAL) has entered into a sale and leaseback agreement of its $33.1 million manufacturing site in Melbourne.
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima (ASX:HXL) completes $1m SPP

Biotechnology company Hexima (HXL) has successfully completed its share purchase plan (SPP) and raised $1 million.

" Paragon Care (ASX:PGC) enters partnership with Centuria Healthcare for a healthcare facility

Paragon Care (PGC) has entered into a partnership with Centuria Healthcare for the 15-year lease of a state-of-the-art healthcare facility in Melbourne.